Results 11 to 20 of about 898,102 (296)
ING1 inhibits Twist1 expression to block EMT and is antagonized by the HDAC inhibitor vorinostat
ING1 is a chromatin targeting subunit of the Sin3a histone deacetylase (HDAC) complex that alters chromatin structure to subsequently regulate gene expression.
Yang Yang +14 more
doaj +2 more sources
In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC) [PDF]
Background The cervical cancer is the second most prevalent cancer for the woman in the world. It is caused by the oncogenic human papilloma virus (HPV).
Tambunan Usman SF +2 more
doaj +2 more sources
HDAC/MIF dual inhibitor inhibits NSCLC cell survival and proliferation by blocking the AKT pathway [PDF]
Non-small-cell lung carcinoma (NSCLC) is one of the most common forms of lung cancer, and a leading cause of cancer death among human beings. There is an urgent demand for novel therapeutics for the treatment of NSCLC to enhance the efficacy of the ...
Chen, Siwei; id_orcid +13 more
core +1 more source
A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. [PDF]
BACKGROUND: Lung cancer is the leading cause of cancer mortality worldwide, yet the therapeutic strategy for advanced non-small cell lung cancer (NSCLC) is limitedly effective.
Yen-An Tang +8 more
doaj +1 more source
Azumamides A-E: Isolation, Synthesis, Biological Activity, and Structure–Activity Relationship
Cyclic peptides are one of the important chemical groups in the HDAC inhibitor family. Following the success of romidepsin in the clinic, naturally occurring cyclic peptides with a hydrophilic moiety have been intensively studied to test their function ...
Sooheum Jo +4 more
doaj +1 more source
Histone deacetylase (HDAC) inhibitors and proteasome inhibitors have been approved by the FDA for the treatment of multiple myeloma and lymphoma, respectively, but have not achieved similar activity as single agents in solid tumors.
Jianling Bi +7 more
doaj +1 more source
HDACs and HDAC Inhibitors in Cancer Development and Therapy [PDF]
Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play a crucial role in cancer development and progression by modulating gene transcription, chromatin remodeling, and nuclear architecture.
Yixuan, Li, Edward, Seto
openaire +2 more sources
Background Multiple myeloma (MM) is an incurable disease. The acquisition of resistance to drugs, including immunomodulatory drugs (IMiDs), has a negative effect on its prognosis.
Mitsuhito Hirano +19 more
doaj +1 more source
Epithelial-to-mesenchymal transition (EMT) is an essential mechanism for development and wound healing, but in cancer it also mediates the progression and spread of aggressive tumors while increasing therapeutic resistance.
Thais Oliveira +5 more
doaj +1 more source
Background Histone deacetylase (HDAC) inhibitors are promising anticancer drugs but their effect on tumor treatment has been disappointing mainly due to the acquisition of HDAC inhibitor resistance.
Won Chan Hwang +5 more
doaj +1 more source

